These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 23771499)

  • 41. The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
    Filippatos TD; Athyros VG; Elisaf MS
    Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):787-812. PubMed ID: 24746233
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
    Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA
    Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus.
    Yang SJ; Min KW; Gupta SK; Park JY; K Shivane V; Agarwal PK; Kim DM; Kim YE; Baik SH
    Diabetes Metab J; 2021 Jul; 45(4):606-612. PubMed ID: 33081425
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
    Bailey CJ; Green BD; Flatt PR
    Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A prospective cohort study on effects of gemigliptin on cardiovascular outcomes in patients with type 2 diabetes (OPTIMUS study).
    Kim EH; Kim SS; Kim DJ; Choi YS; Lee CW; Ku BJ; Cha KS; Song KH; Kim DK; Kim IJ
    Sci Rep; 2020 Nov; 10(1):19033. PubMed ID: 33149182
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects.
    Cho YS; Lee SH; Lim HS; Bae KS
    J Korean Med Sci; 2018 Oct; 33(41):e258. PubMed ID: 30288156
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Absorption, metabolism and excretion of [14C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
    Kim N; Patrick L; Mair S; Stevens L; Ford G; Birks V; Lee SH
    Xenobiotica; 2014 Jun; 44(6):522-30. PubMed ID: 24304170
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus.
    Jin L; Lim SW; Jin J; Chung BH; Yang CW
    Transl Res; 2016 Aug; 174():122-39. PubMed ID: 27059001
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
    Barnett AH
    Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
    Forst T; Pfützner A
    Expert Opin Pharmacother; 2012 Jan; 13(1):101-10. PubMed ID: 22149370
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial.
    Trakarnvanich T; Satirapoj B; Suraamornkul S; Chirananthavat T; Sanpatchayapong A; Claimon T
    J Diabetes Res; 2021; 2021():7382620. PubMed ID: 34697593
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metformin + saxagliptin for type 2 diabetes.
    Scheen AJ
    Expert Opin Pharmacother; 2012 Jan; 13(1):139-46. PubMed ID: 22149373
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical review of sitagliptin: a DPP-4 inhibitor.
    Garg K; Tripathi CD; Kumar S
    J Assoc Physicians India; 2013 Sep; 61(9):645-9. PubMed ID: 24772702
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comparison of intensive insulin therapy and dipeptidyl peptidase-4 inhibitor plus metformin combination in newly diagnosed type 2 diabetes mellitus.
    Diri H; Bolayir B; Soylu H; Cetin S; Simsek M
    Minerva Endocrinol (Torino); 2024 Jun; 49(2):228-230. PubMed ID: 37158810
    [No Abstract]   [Full Text] [Related]  

  • 56. The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin.
    Hamasaki H; Yanai H
    Int J Cardiol; 2013 Oct; 168(3):e106. PubMed ID: 23972359
    [No Abstract]   [Full Text] [Related]  

  • 57. DPP IV inhibitors: successes, failures and future prospects.
    Kshirsagar AD; Aggarwal AS; Harle UN; Deshpande AD
    Diabetes Metab Syndr; 2011; 5(2):105-12. PubMed ID: 22813415
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.
    Kim TE; Lim KS; Park MK; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Sep; 34(9):1986-98. PubMed ID: 22943970
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.
    Biftu T; Sinha-Roy R; Chen P; Qian X; Feng D; Kuethe JT; Scapin G; Gao YD; Yan Y; Krueger D; Bak A; Eiermann G; He J; Cox J; Hicks J; Lyons K; He H; Salituro G; Tong S; Patel S; Doss G; Petrov A; Wu J; Xu SS; Sewall C; Zhang X; Zhang B; Thornberry NA; Weber AE
    J Med Chem; 2014 Apr; 57(8):3205-12. PubMed ID: 24660890
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes.
    Lajara R
    Expert Opin Pharmacother; 2012 Dec; 13(18):2663-71. PubMed ID: 23137412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.